Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Gains from Sales and Divestitures: 2017-2025

Historic Gains from Sales and Divestitures for Enanta Pharmaceuticals (ENTA) over the last 9 years, with Sep 2025 value amounting to $152,000.

  • Enanta Pharmaceuticals' Gains from Sales and Divestitures rose 24.59% to $152,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $152,000, marking a year-over-year increase of 24.59%. This contributed to the annual value of $152,000 for FY2025, which is 24.59% up from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Gains from Sales and Divestitures is $152,000, which was up 4.11% from $146,000 recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Gains from Sales and Divestitures high stood at $152,000 for Q3 2025, and its period low was $29,000 during Q4 2021.
  • Its 3-year average for Gains from Sales and Divestitures is $115,182, with a median of $116,000 in 2024.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Gains from Sales and Divestitures crashed by 35.56% in 2021 and then spiked by 141.38% in 2023.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Gains from Sales and Divestitures stood at $29,000 in 2021, then skyrocketed by 93.10% to $56,000 in 2022, then skyrocketed by 107.14% to $116,000 in 2023, then rose by 24.14% to $144,000 in 2024, then rose by 24.59% to $152,000 in 2025.
  • Its last three reported values are $152,000 in Q3 2025, $146,000 for Q2 2025, and $145,000 during Q1 2025.